Analysis of the mechanism of action of Momelotinib and the principle of targeted treatment of myelofibrosis

Momelotinib (trade name Ojjaara) is a new oral triple target inhibitor of JAK1/JAK2 and ACVR1 developed by Sierra Oncology (later acquired by GSK) was developed. The drug was officially approved by the FDA in 2023 for the treatment of patients with intermediate- and high-risk myelofibrosis (MF) accompanied by anemia. Myelofibrosis is a myeloproliferative neoplasm derived from hematopoietic stem cell mutations and is characterized by bone marrow fibrosis, splenomegaly, and hematological abnormalities. The development goal of molotinib is to simultaneously control inflammatory signals, improve anemia, and relieve symptoms of splenomegaly, thereby achieving multiple benefits for the disease.

The core mechanism of action of molotinib is to inhibit the JAK-STAT signaling pathway. Patients with myelofibrosis often have driver mutations such as JAK2 V617F or CALR, MPL. These mutations can lead to the continued activation of JAK-STAT signaling, abnormal proliferation of hematopoietic cells, and excessive release of inflammatory factors. Molotinib inhibits JAK1 and JAK2 kinase activities and blocks abnormal signaling, thereby reducing spleen enlargement and the progression of myelofibrosis. In addition, molotinib uniquely inhibits ACVR1 (activin A receptor type I), which can reduce Hepcidin (hepcidin) levels in the body and promote iron utilization and erythropoiesis, which is an important molecular mechanism for improving anemia.

In the pivotalIII study (SIMPLIFY-1 and SIMPL In the IFY-2 trial), molotinib showed similar spleen shrinkage rates compared with ruxolitinib (Ruxolitinib), but had a significant advantage in improving anemia. About 30% to 40% of patients can reduce their dependence on blood transfusions after treatment, and some even recover their autonomous hematopoietic function. Research shows that molotinib not only controls the inflammatory response and relieves BSymptoms (such as fatigue, night sweats, weight loss), it also increases the red blood cell production rate by regulating iron metabolism pathways, achieving the dual clinical benefit of "anti-fibrosis+improvement of anemia". This mechanism breaks through the limitation of traditional JAK inhibitors that only relieve symptoms but do not improve anemia.

Clinical significance and future prospects The emergence of molotinib marks the transition of myelofibrosis treatment from"simple inhibition ofJAK" to the stage of "multi-target precise regulation". Its mechanism of simultaneously acting on JAK1/JAK2 and ACVR1 makes it the first drug to have triple effects of anti-inflammation, anti-fibrosis and improving anemia. Clinical experts generally believe that molotinib is suitable for MF patients with moderate to severe anemia or requiring blood transfusions, and is expected to improve long-term prognosis and quality of life. Future studies will focus on its potential in early stage MF, in combination with hypomethylating drugs, and in combination with novel JAK inhibitors such as Pacritinib. Overall, molotinib provides a new treatment model and hope for the precise treatment of myelofibrosis through multi-target regulation.

Reference materials:https://www.drugs.com/